Haemacure to get $5 million investment from Swiss Red Cross:
This article was originally published in Clinica
Haemacure is negotiating the terms of a SwFr7 million ($4.7 million) investment from ZLB, the central laboratory of the Swiss Red Cross. The funds will be used to launch Hemaseal APR, the Montreal-based company's fibrin sealant, the first such product to receive FDA approval. The product is used to stop bleeding and seal wounds in surgical procedures involving cardiopulmonary bypass, colostomy closure and spleen injuries.